Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children Ages 2-17

Phase 1

Completed

• Conditions: Neutropenia

• Registration Number: NCT00056381
• Lead Sponsor: Pfizer

Brief Summary

Anidulafungin is a medicine being developed for treatment of adults with certain kinds of fungal infections. This study is evaluating anidulafungin in children and adolescents who have fever and a low white blood cell count (neutropenia).

Detailed Description

Anidulafungin is an investigational drug being developed as an intravenous treatment for esophageal candidiasis, candidemia and other invasive fungal infections. Anidulafungin is an antifungal agent of the echinocandin class, which targets the fungal cell wall of yeast and other filamentous fungi.

Study Timeline

• Study First Submitted: 2003-03-11
• Study First Submitted QC: 2003-03-11
• Study First Posted: 2003-03-12
• Study Start: 2003-07
• Study Completion: 2004-06
• Status Verified: 2008-10
• Last Update Submitted: 2008-10-17
• Last Update Posted: 2008-10-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Trial Locations

Locations (1)

Versicor; 🇺🇸 King of Prussia, Pennsylvania, United States